UPDATE: This investigation is now closed. For further assistance, we recommend reaching out to an attorney who specializes in individual based personal injury suits and may be able to better evaluate your potential claims.
Migliaccio & Rathod is currently investigating Pfizer’s recall of blood pressure medication Accuretic, for containing the known carcinogen N-nitroso-quinapril, a nitrosamine, in amounts that exceed Acceptable Daily Intake (ADI) levels. The recall also includes two authorized generics distributed by Greenstone (quinapril and hydrochlorothiazide and quinapril HCl/ hydrochlorothiazide). Prolonged exposure to nitrosamines above acceptable levels over time increases the patient’s risk of developing cancer. Pfizer currently advises patients taking this medication to consult with their doctors and switch to another blood pressure medication. The affected product lots are reproduced below:
Accuretic™ (quinapril HCl/hydrochlorothiazide) tablets, 10/12.5 mg
Accuretic™ (quinapril HCl/hydrochlorothiazide) tablets, 20/12.5 mg
Accuretic™ (quinapril HCl/hydrochlorothiazide) tablets, 20/25 mg
| NDC | Lot Number | Expiration Date | Strength | Configuration/Count |
| 0071-3112-23 |
FG5379 |
08/2024 | 10/12.5 mg | 1 x 90 count bottle |
| 0071-0222-23 |
EA6686 |
04/2022 | 10/12.5 mg | 1 x 90 count bottle |
| 0071-5212-23 |
FG5381 |
08/2024 | 20/12.5 mg | 1 x 90 count bottle |
| 0071-0220-23 |
EA6665 |
04/2022 | 20/12.5 mg | 1 x 90 count bottle |
| 0071-0220-23 |
CN0640 |
04/2022 | 20/12.5 mg | 1 x 90 count bottle |
| 0071-0223-23 |
ET6974 |
02/2023 | 20/25 mg | 1 x 90 count bottle |
quinapril and hydrochlorothiazide tablets, 20/25 mg
quinapril HCl/hydrochlorothiazide tablets, 20/12.5 mg
quinapril HCl/hydrochlorothiazide tablets, 20/25 mg
| NDC | Lot Number | Expiration Date | Strength | Configuration/Count |
| 59762-5225-9 |
FE3714 |
02/2023 | 20/25 mg | 1 x 90 count bottle |
| 59762-0220-1 |
DN6931 |
03/2023 | 20/12.5 mg | 1 x 90 count bottle |
| 59762-0220-1 |
ED3904 |
03/2023 | 20/12.5 mg | 1 x 90 count bottle |
| 59762-0220-1 |
ED3905 |
03/2023 | 20/12.5 mg | 1 x 90 count bottle |
| 59762-0223-1 |
DP3414 |
02/2023 | 20/25 mg | 1 x 90 count bottle |
UPDATE (4/25/2022): Pfizer Inc. is recalling several lots of a blood pressure drug due to elevated levels of a potential cancer-causing impurity.
The recalled product lots were distributed nationwide to wholesalers and distributors in the United States and Puerto Rico from December 2019 to April 2022, according to the FDA notice. The impacted products include:
Accupril® (Quinapril HCl Tablets), 10 mg
Accupril® (Quinapril HCl Tablets), 20 mg
Accupril® (Quinapril HCl Tablets), 40 mg
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/cmg/TS4DY3L55RE6NOE42RICJCTJRE.png)
Did you take medicines containing quinapril and were you notified of the FDA’s recall?
If so, we would like to hear from you. Please complete the questionnaire below, send us an email at [email protected], or call us at (202) 470-3520 for more information.
Committed to Consumer Protection
The lawyers at Migliaccio & Rathod LLP have years of experience in class action litigation against large corporations, including in cases involving data breaches and product defects. More information about our current cases and investigations is available on our blog.